Quarry LP purchased a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,000 shares of the company’s stock, valued at approximately $83,000.
A number of other large investors also recently bought and sold shares of the business. Wildcat Capital Management LLC purchased a new stake in Praxis Precision Medicines in the 4th quarter worth $373,000. PCG Wealth Advisors LLC acquired a new position in Praxis Precision Medicines in the 1st quarter valued at $788,000. BNP Paribas Financial Markets purchased a new position in Praxis Precision Medicines in the 1st quarter valued at $412,000. Chase Investment Counsel Corp acquired a new stake in Praxis Precision Medicines during the 1st quarter worth $229,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Praxis Precision Medicines during the first quarter worth $150,000. Institutional investors and hedge funds own 67.84% of the company’s stock.
Praxis Precision Medicines Price Performance
PRAX stock opened at $61.14 on Thursday. The business’s 50-day moving average is $55.81 and its two-hundred day moving average is $51.00. The firm has a market capitalization of $1.05 billion, a P/E ratio of -3.85 and a beta of 2.73. Praxis Precision Medicines, Inc. has a 1 year low of $13.01 and a 1 year high of $67.21.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on PRAX. Oppenheimer reiterated an “outperform” rating and set a $143.00 price objective (up previously from $134.00) on shares of Praxis Precision Medicines in a research report on Wednesday, September 4th. Guggenheim boosted their target price on shares of Praxis Precision Medicines from $155.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Piper Sandler restated an “overweight” rating and set a $270.00 price target on shares of Praxis Precision Medicines in a report on Monday, July 1st. Needham & Company LLC reiterated a “buy” rating and issued a $145.00 price objective on shares of Praxis Precision Medicines in a report on Tuesday, September 3rd. Finally, Wedbush upped their price target on Praxis Precision Medicines from $40.00 to $48.00 and gave the company a “neutral” rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $143.44.
View Our Latest Analysis on Praxis Precision Medicines
Praxis Precision Medicines Company Profile
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Read More
- Five stocks we like better than Praxis Precision Medicines
- What Investors Need to Know to Beat the Market
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Best Stocks Under $10.00
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Stock Dividend Cuts Happen Are You Ready?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.